Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.53 |
| ▸ | F12 | P00748 | 2/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28285945 | 0.86 | ROCK1 (0.72) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL6436256 | 0.84 | ROCK1 (0.74) | PLAUROCK1F12NCF1NOS3 | |
| Hydrochloric Acid SCHEMBL16246756 | 0.82 | ROCK1 (0.72) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL6982094 | 0.82 | ROCK1 (0.53) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL24358795 | 0.81 | ROCK1 (0.51) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL29732356 | 0.81 | ROCK1 (0.51) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL6997520 | 0.79 | PLAU (0.56) | PLAUROCK1RECQLMAOADYRK1A | |
| SCHEMBL15732187 | 0.78 | ROCK1 (0.49) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL6435603 | 0.76 | F12 (0.53) | PLAUROCK1F12NCF1NOS3 | |
| SCHEMBL29508479 | 0.75 | F12 (0.57) | PLAUROCK1F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012166-B1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2003-10-29 | — | — | EP | disclosed |
| US-6420438-B1 | FOR THERAPY OF THROMBOTIC DISEASE, ASTHMA, EMPHYSEMA, CIRRHOSIS, ARTHRITIS, CARCINOMA, MELANOMA, RESTENOIS, ATHEROMA, TRAUMA, SHOCK AND REPERFUSION INJURY | TULARIK LIMITED (GB) | 2002-07-16 | — | — | US | disclosed |
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6262069-B1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1012166-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | Protherics Molecular Design Limited (GB) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999011657-A1 | 1-AMINO-7-ISOQUINOLINE DERIVATIVES AS SERINE PROTEASE INHIBITORS | PROTEUS MOLECULAR DESIGN LTD. (GB) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | PLAU 321/4885ROCK1 2995/4885F12 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.